Shots:
- The P-III (frontMIND) trial assessed Monjuvi (Minjuvi in EU) + lenalidomide & R-CHOP vs R-CHOP as the 1L treatment in ~900 adults with previously untreated DLBCL (IPI score of 3-5 for pts >60yrs or aaIPI of 2-3 for pts ≤60yrs.)
- Trial met its 1EP of improved PFS by investigator assessment & achieved its key 2EP of improved EFS by investigator assessment; data to be presented at an upcoming meeting
- Based on positive frontMIND results, Incyte is planning to submit an sBLA for Monjuvi + lenalidomide & R-CHOP as a 1L treatment for newly diagnosed adult DLBCL in H1’26
Ref: Incyte | Image: Incyte | Press Release
Related News: Incyte’s Minjuvi (Tafasitamab) Combination Gains the MHLW Approval for R/R Follicular Lymphoma (FL)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
